Newly Diagnosed Intermediate/High-Risk MDS
1 clinical trials · Condition
◉ Watch Newly Diagnosed Intermediate/High-Risk MDS
| Record | Firm | Date |
|---|---|---|
| Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications (NCT02649790) | Karyopharm Therapeutics Inc | 2016-01-01 |
Track Newly Diagnosed Intermediate/High-Risk MDS automatically
Every clearance here is in the API, with alerts when new ones post.